Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 293

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 293
---
 issuance costs— 49,824 Merger transaction costs— (2,360)Net cash provided by financing activities26,532 169,131 Net increase in cash, cash equivalents, and restricted cash17,450 49,009 Cash and cash equivalents, and restricted cash, beginning of the period20,272 35,140 Cash, cash equivalents, and restricted cash, end of the period$37,722 $84,149 Supplemental cash flow informationConversion of Series A, A-1, and B convertible preferred stock to common stock$— $137,490 Conversion of Class B convertible common stock to common stock$— $5,900 Reclassification of warrant liability to equity$— $1,918 Prepaid expenses and other current assets assumed in the Merger$— $1,313 Accounts payable and accrued liabilities assumed in the Merger$— $2,950 Merger transaction costs included in accounts payable and accrued expenses$— $42 Right-of-use assets assumed in the Merger in exchange for operating lease liabilities$— $218 Right-of-use assets obtained in exchange for operating lease liabilities$— $1,218 Property and equipment included in accounts payable$225 $— 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

6

LENZ THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

(unaudited)

1.    Organization and Liquidity 

Description of the BusinessLENZ Therapeutics, Inc. (“LENZ” or the “Company”), formerly known as Graphite Bio, Inc. (“Graphite”), was incorporated in Ontario, Canada in June 2017 as Longbow Therapeutics Inc., and was reincorporated in the State of Delaware in October 2019. The Company has a wholly owned subsidiary, LENZ Therapeutics Operations, Inc. (“LENZ OpCo”), previously named Lenz Therapeutics, Inc., which became a corporation in Delaware on October 28, 2020 upon the filing of a Certificate of Conversion to convert Presbyopia Therapies, LLC, a Delaware limited liability company (formed in September 2013), to a Delaware corporation. The Company is a pre-commercial biopharmaceutical company focused on the development and commercialization of innovative therapies to improve vision.Reverse Merger TransactionOn March 21, 202